The Edoxaban Hokusai VTE PEDIATRICS Study: An open‐label, multicenter, randomized study of edoxaban for pediatric venous thromboembolic disease [PDF]
Research and Practice in Thrombosis and Haemostasis, 2020 Background Little evidence is available for treatment of pediatric venous thromboembolism (VTE). Large randomized controlled trials are challenging in children.
Guy Young +2 more
exaly +3 more sources
The edoxaban‐M4 metabolite and measurement of edoxaban by chromogenic assays in human plasma
Research and Practice in Thrombosis and Haemostasis, 2022 Introduction Edoxaban is the only anti‐Xa inhibitor metabolized in pharmacologically active moiety that could interfere with chromogenic anti‐Xa assays, especially in case of drug‐drug interactions or physiological disorders.
Romain Siriez +9 more
doaj +2 more sources
Early experiences with edoxaban for stroke prevention in atrial fibrillation in the Southeast Asia region [PDF]
Drugs in Context, 2023 Edoxaban, a once-daily, direct-acting oral anticoagulant, is approved to prevent stroke or systemic embolism in non-valvular atrial fibrillation (NVAF) and treat venous thromboembolism.
Alejandro Bimbo Diaz +8 more
doaj +2 more sources
Andexanet alfa effectively reverses edoxaban anticoagulation effects and associated bleeding in a rabbit acute hemorrhage model. [PDF]
PLoS ONE, 2018 Increasing use of factor Xa (FXa) inhibitors necessitates effective reversal agents to manage bleeding. Andexanet alfa, a novel modified recombinant human FXa, rapidly reverses the anticoagulation effects of direct and indirect FXa inhibitors.To evaluate
Genmin Lu +9 more
doaj +2 more sources
Diffuse Alveolar Hemorrhage Associated with Edoxaban Therapy [PDF]
Case Reports in Critical Care, 2016 Introduction. The main adverse effect of anticoagulant therapy is bleeding, and major bleeding, including intracranial, gastrointestinal, and retroperitoneal bleeding, has been reported as an adverse effect of edoxaban, a direct oral anticoagulant (DOAC).
Kenichi Nitta +4 more
doaj +2 more sources
Edoxaban for stroke prevention in Chinese patients with atrial fibrillation: 1-year follow-up of the ETNA-AF-China study [PDF]
Frontiers in PharmacologyIntroductionNon–vitamin K antagonist oral anticoagulants (NOACs) are the first-line therapy to prevent ischaemic stroke in patients with atrial fibrillation (AF).
Xueyuan Guo +24 more
doaj +2 more sources
Edoxaban in venous thromboembolism and stroke prevention: an appraisal [PDF]
Vascular Health and Risk Management, 2016 Marco Proietti,1,2 Gregory YH Lip1,3 1University of Birmingham Institute of Cardiovascular Sciences, City Hospital, Birmingham, UK; 2Department of Internal Medicine and Medical Specialties, Sapienza-University of Rome, Rome, Italy; 3Aalborg Thrombosis ...
Proietti M, Lip GYH
doaj +2 more sources
Edoxaban pharmacokinetics during in vitro continuous renal replacement therapy
BMC NephrologyBackground To evaluate the clearance of edoxaban during modeled in vitro continuous renal replacement therapy (CRRT), assess protein binding and circuit adsorption, and provide initial dosing recommendations.
Eric Wenzler +3 more
doaj +2 more sources
pharma-kritik, 2018 Ein weiteres «direktes» orales Antikoagulans, das weniger Blutungen verursacht als Warfarin. In welchem Ausmass sich die Studienresultate auf einen Vergleich mit dem in der Schweiz gebräuchlichen Phenprocoumon extrapolieren lassen, ist nicht klar.
Lenka Špinarová +2 more
+7 more sources
Edoxaban Monotherapy and Incidence of Transcatheter Heart Valve Leaflet Thrombosis - The Rotterdam Edoxaban (REDOX) Study [PDF]
BACKGROUND: Trials comparing non-vitamin K oral anticoagulant (NOAC) versus antiplatelet-based strategies have shown a reduction of subclinical leaflet thrombosis at the cost of increased mortality and major-bleedings.
van Wiechen, Maarten P +12 more
core +13 more sources